US Revenue
$229M
+28% YoY
Highest ever quarterly US revenue, driven by lanreotide and albuterol share gains.
CIPLA
Healthcare
27 Oct 2023
Cipla Ltd — Q2 FY24
Cipla delivered a record quarter with revenue of ₹6,678 crore (+15% YoY) and EBITDA margin of 26%, driven by double-digit growth across India (+10%), North America (+28% to $229M), and South Africa (+12%).
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Cipla delivered a record quarter with revenue of ₹6,678 crore (+15% YoY) and EBITDA margin of 26%, driven by double-digit growth across India (+10%), North America (+28% to $229M), and South Africa (+12%). The India business benefited from a chronic mix shift (+140bps to 60%), while US growth was led by lanreotide (20% share) and albuterol share recovery. EBITDA guidance was raised to 23-24% (bias to higher end). Key upcoming catalysts include generic Symbicort filing in Q3, a peptide launch in Q4, and multiple complex filings in FY25. Risk: Indore facility OAI classification could delay US approvals.
सिप्ला ने एक रिकॉर्ड तिमाही दर्ज की। कुल कमाई ₹6,678 करोड़ रही, जो पिछले साल से 15% ज़्यादा है। मुनाफा (EBITDA) 26% रहा। भारत में बिक्री 10%, उत्तर अमेरिका में 28% ($229 मिलियन) और दक्षिण अफ्रीका में 12% बढ़ी। भारत में पुरानी बीमारियों की दवाओं की हिस्सेदारी बढ़कर 60% हो गई। अमेरिका में लैनरियोटाइड (20% बाजार हिस्सा) और एल्ब्युटेरोल की बिक्री बढ़ी। कंपनी ने मुनाफा अनुमान 23-24% तक बढ़ा दिया। आने वाले समय में जेनेरिक सिम्बिकॉर्ट (तीसरी तिमाही), एक पेप्टाइड दवा (चौथी तिमाही) और कई जटिल दवाएं लॉन्च होंगी। जोखिम: इंदौर फैक्ट्री पर OAI वर्गीकरण से अमेरिकी मंजूरी में देरी हो सकती है।
Key Numbers
India Chronic Mix
60%
+140bps YoY
Chronic share of India portfolio improved, supporting margin expansion.
Lanreotide Market Share
20%
N/A
Market share in lanreotide improved to 20% as of August 2023.
Albuterol Market Share
12.9%
+90bps QoQ
Albuterol share improved 90bps from Q1 FY24 to 12.9%.
What Changed vs Last Quarter
NEW
EBITDA margin guidance raised to 23-24% for FY24
Management increased full-year EBITDA margin guidance from 23% to 23-24%, with bias towards the higher end.
NEW
Peptide product launch in Q4 FY24
One peptide product launch planned in Q4 FY24, with 3-4 more in FY25.
NEW
US revenue sustainable range of $220-225M next quarter
Management guided US revenue of $220-225M as sustainable for the next quarter.
UPDATED
Generic Symbicort filing in Q3 FY24
Cipla plans to file generic Symbicort in Q3 FY24, having completed clinical studies.
DROPPED
Full-year EBITDA margin target of ~23%
Management raised FY24 EBITDA margin guidance to approximately 23%, up from earlier 22% guidance, driven by strong Q1 performance and confidence across markets.
DROPPED
4-5 peptide launches in next two years
Cipla plans to launch 4-5 peptide products over the next two years, with a couple of new peptide filings in the same period.
DROPPED
Advair launch within 12 months via de-risking
Generic Advair is being transferred to an in-house facility; launch expected within 12 months with no incremental generic competition anticipated.
NEW RISK
Revlimid volume uncertainty post-12-month period
Analyst questioned Revlimid volume trajectory after the initial 12-month period; management gave no specific guidance.
RISK GONE
Potential pricing pressure in US generics
While price erosion has eased, management noted it could revert to higher levels in later quarters, impacting US revenue sustainability.
RISK GONE
Goa facility re-inspection uncertainty
Cipla's Goa facility is under remediation and expects re-inspection in H2 FY24. Any adverse outcome could disrupt supply of key products.
Management Guidance
EBITDA margin guidance raised to 23-24% for FY24
Management increased full-year EBITDA margin guidance from 23% to 23-24%, with bias towards the higher end.
Management guidance marginsGeneric Symbicort filing in Q3 FY24
Cipla plans to file generic Symbicort in Q3 FY24, having completed clinical studies.
Management guidance growthPeptide product launch in Q4 FY24
One peptide product launch planned in Q4 FY24, with 3-4 more in FY25.
Management guidance growthUS revenue sustainable range of $220-225M next quarter
Management guided US revenue of $220-225M as sustainable for the next quarter.
Management guidance revenueKey Risks
Indore facility OAI classification
Indore facility received OAI from US FDA; corrective measures are ongoing but may delay US approvals.
high · management_commentaryAlbuterol market share volatility
Albuterol share is dependent on which variant the market buys; recovery to prior highs is not fully in Cipla's control.
medium · analyst_questionRevlimid volume uncertainty post-12-month period
Analyst questioned Revlimid volume trajectory after the initial 12-month period; management gave no specific guidance.
medium · analyst_questionNotable Quotes
In quarter two of FY 2024, we have continued the trend of strong performance, and we have recorded our highest ever quarterly revenue at INR 6,678 crores, with a year-on-year growth of 15% and a EBITDA margin of 26%.
Our EBITDA for the year is trending in the range of, so we are increasing our guidance on EBITDA from 23%, what we had given earlier, to 23%-24%, with bias towards the higher end.
I think the market size of that product could be, you know, anywhere upwards from $300 million-$400 million.
Frequently Asked Questions
What was Cipla's revenue in Q2 FY24?
Cipla reported revenue of ₹6,678 Cr in Q2 FY24, representing a +15% change compared to the same quarter last year.
What guidance did Cipla management give for FY25?
EBITDA margin guidance raised to 23-24% for FY24: Management increased full-year EBITDA margin guidance from 23% to 23-24%, with bias towards the higher end. Generic Symbicort filing in Q3 FY24: Cipla plans to file generic Symbicort in Q3 FY24, having completed clinical studies. Peptide product launch in Q4 FY24: One peptide product launch planned in Q4 FY24, with 3-4 more in FY25. US revenue sustainable range of $220-225M next quarter: Management guided US revenue of $220-225M as sustainable for the next quarter.
What are the key risks for Cipla in FY25?
Key risks include Indore facility OAI classification — Indore facility received OAI from US FDA; corrective measures are ongoing but may delay US approvals.; Albuterol market share volatility — Albuterol share is dependent on which variant the market buys; recovery to prior highs is not fully in Cipla's control.; Revlimid volume uncertainty post-12-month period — Analyst questioned Revlimid volume trajectory after the initial 12-month period; management gave no specific guidance..
Did Cipla meet its previous quarter's guidance?
Of 1 tracked promise, management 0 met, 0 close, 1 missed.
Where can I read the full Cipla Q2 FY24 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.